Global Vinflunine Market, By Drug Class (Antineoplastics, Vinca Alkaloids), Indication (Oncology/Cancer, Others), Dosage Forms (Solution, Injections, Others), Route of Administration (Intravenous, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.
Vinflunine Market Analysis and Size
Cancer is the greatest cause of mortality worldwide, according to the World Health Organization (WHO), accounting for approximately 10 million deaths in 2020, or nearly one in every six deaths. Around 400,000 children are diagnosed with cancer every year. Vinflunine is a form of vinca alkaloid that is commonly used to treat cancer. It belongs to the third generation of vinca alkaloids having anti-tumor properties. It works by stimulating cell cycle arrest in the G2/M phase and promoting cell death through apoptosis. The European Medicines Agency approved it in 2009 as a second-line therapy for urothelial carcinoma when platinum treatment failed.
Data Bridge Market Research analyses that the global vinflunine market which was USD 8,475.23 million in 2022, would rocket up to USD 15,746.14 million by 2030, and is expected to undergo a CAGR of 11.2% during the forecast period. This indicates that the market value. “Antineoplastics” is expected to dominate the drug class segment of the global vinflunine market owing to the high demand for this type of drug. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Vinflunine Market Scope and Segmentation
2023 to 2030
2021 (Customizable to 2015-2020)
Revenue in USD Million, Volumes in Units, Pricing in USD
Drug Class (Antineoplastics, Vinca Alkaloids), Indication (Oncology/Cancer, Others), Dosage Forms (Solution, Injections, Others), Route of Administration (Intravenous, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Market Players Covered
AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Fresenius Kabi AG (Germany), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Sanofi (France), Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb Company (U.S.), Abbott (U.S.), Sagent Pharmaceuticals, Inc. (U.S.), Hikma Pharmaceuticals PLC (U.K.), Dr. Reddy’s Laboratories Ltd. (India), Eli Lilly and Company (U.S.), Aurobindo Pharma (India), Amneal Pharmaceuticals LLC. (U.S.)
After a platinum-based treatment has failed, vinflunine is a vinca alkaloid used to treat advanced or metastatic transitional cell carcinoma of the urothelial tract. Vinflunine's antitumor effects are depending on the drug's concentration and exposure time. Vinflunine inhibits microtubule assembly and reduces the rate and extent of microtubule growth events at micromolar doses, resulting in an anti-mitotic effect. In mice, vinflunine has an anti-cancer effect against a wide range of human xenografts, both in terms of survival and tumor growth inhibition. In vitro, vinflunine is a less powerful activator of drug resistance than other vinca alkaloids.
Vinflunine Market Dynamics
- The rise in the prevalence of cancer
The rising prevalence of cancer such as urothelial cancer, cell carcinoma, and others is estimated to enhance the vinflunine market's growth rate. Urothelial carcinoma of the bladder is one of the most frequent cancers globally, with an annual incidence of 429,700 new cases and a fatality rate of 165,000. Approximately 80% of those affected are between the ages of 50 and 79. Surgical techniques are preferable for non-muscle-invasive bladder cancer and muscle-invasive locally restricted malignancies.
- Research and development proficiencies
Rising expenditure for research and development proficiencies especially in the developed and developing economies pertaining to medical instruments and devices will further create lucrative market growth opportunities. Research and development proficiencies being conducted for the integration of advanced technologies in healthcare facilities is also bolstering the market growth rate.
- Growing investment for healthcare facilities
Surging focus on improving the condition of healthcare facilities and improving the overall healthcare infrastructure is another important factor fostering the growth of the market. The rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.
- Expansion of the pharmaceutical industry
The pharmaceutical industry is experiencing growth due to various factors, including advancements in device development, increasing investments in research and development, and expanding healthcare infrastructure. This growth directly impacts the Vinflunine market.
Government investments in healthcare infrastructure
The increase in funding by the federal government is set to drive the market growth rate. Moreover, the growth and expansion of the healthcare industry being driven by both public and private players, especially in developing economies will create lucrative market growth opportunities. Also, the high return on investments assured by the research activities will work in the favor of the market.
- Rising competition
The vinflunine market is highly competitive, with numerous companies offering a wide range of products. This can make it challenging for new entrants or smaller companies to gain market share and establish a strong presence.
High cost associated with drug development and distribution
The cost of drug development and distribution is very high in the market. Healthcare systems and payers face cost pressures, and there is a growing demand for cost-effective solutions. Manufacturers need to balance the development of innovative implants with affordability to meet market demands.
This vinflunine market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Vinflunine Market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
- In July 2021, Pierre Fabre a pharmaceutical company developed Vinflunine (brand name: Javlor). Vinflunine is a chemotherapy drug approved for the treatment of advanced or metastatic urothelial carcinoma. Pierre Fabre continues to focus on research and development to explore the potential of Vinflunine in other cancer indications and improve its therapeutic applications
- In August 2021, Mylan is a global pharmaceutical company that has been involved in the marketing and distribution of Vinflunine in various regions. Mylan has worked to expand access to Vinflunine for patients with advanced or metastatic urothelial carcinoma in different markets.
Global Vinflunine Market Scope
The VINFLUNINE market is segmented on the basis of drug class, indication, dosage forms, route of administration, end-users, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Vinca Alkaloids
Route of Administration
- Specialty Clinics
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Vinflunine Market Regional Analysis/Insights
The vinflunine market is analysed and market size insights and trends are provided by country, drug class, indication, dosage forms, route of administration, end-users, and distribution channel as referenced above.
The countries covered in the vinflunine market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to dominate the vinflunine market because of the strong base of healthcare facilities, strong presence of major players in the market, and rising number of research activities in this region.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in healthcare facilities, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The Vinflunine market also provides you with detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kind of products for the vinflunine market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the vinflunine Market. The data is available for the historic period 2015-2020.
Competitive Landscape and Global Vinflunine Market Share Analysis
The vinflunine market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to vinflunine market.
Some of the major players operating in the vinflunine market are:
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Fresenius Kabi AG (Germany)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Sanofi (France)
- Merck & Co., Inc. (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Bristol-Myers Squibb Company (U.S.)
- Abbott (U.S.)
- Sagent Pharmaceuticals, Inc. (U.S.)
- Hikma Pharmaceuticals PLC (U.K.)
- Dr. Reddy’s Laboratories Ltd. (India)
- Eli Lilly and Company (U.S.)
- Aurobindo Pharma (India)
- Amneal Pharmaceuticals LLC. (U.S.)